Generic Name and Formulations:
Luliconazole 1%; cream.
Valeant Pharmaceuticals, Inc
Indications for LUZU:
Interdigital tinea pedis, t. cruris, and t. corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
≥18yrs: Apply to affected area and approximately 1 inch of the immediate surrounding area(s) once daily. T. pedis: treat for 2 weeks. T. cruris and t. corporis: treat for 1 week.
<18yrs: not established.
Not for ophthalmic, oral, or intravaginal use. Pregnancy. Nursing mothers.
T. pedis, t. cruris: may inhibit CYP2C19 and CYP3A4 activity.
Application site reactions.
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder